Mymetics’ HIV vaccine candidate confirms promise in preclinical study with the Texas Biomedical Research Institute
Epalinges, April 11 2016
Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys against repeated AIDS virus exposures during part of the preclinical study.
|Media Name||Media Type||Description||Download|
|160411 HIV_Mymetics-Texas Biomed||Download|